Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 4.58 USD -4.98% Market Closed
Market Cap: 25.5m USD
Have any thoughts about
Pluri Inc?
Write Note

Pluri Inc
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pluri Inc
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Pluri Inc
NASDAQ:PLUR
Other Operating Expenses
-$1.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
21%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Other Operating Expenses
-$10k
CAGR 3-Years
48%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Other Operating Expenses
$10k
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pluri Inc
Glance View

Market Cap
25.2m USD
Industry
Biotechnology

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

PLUR Intrinsic Value
1.42 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Pluri Inc's Other Operating Expenses?
Other Operating Expenses
-1.9m USD

Based on the financial report for Sep 30, 2024, Pluri Inc's Other Operating Expenses amounts to -1.9m USD.

What is Pluri Inc's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 10Y
21%

Over the last year, the Other Operating Expenses growth was 87%.

Back to Top